Fundrise VCX Lockup Has Ended: What Happened to the Price

🔄 NAV update, August 28, 2026 — the denominator on this page has changed. Fundrise filed VCX's schedule of investments for June 30, 2026 on August 28, 2026: net assets $776,968,000 and NAV $21.70 per share, up 14.4% from the $18.97 reported for March 31, 2026. Premium figures on this page that were computed against $18.97 were correct for their dates, and are now computed against a superseded NAV. Against the June 30 figure, the August 28 close of $39.84 is a premium of 1.84x (83.6%), not the 2.10x (110.0%) the old denominator gives — a difference of about 26 percentage points. Full position-by-position breakdown, at cost and at mark: VCX's NAV is $21.70, not $18.97.

If you bought VCX after the March 19, 2026 NYSE listing, this article is for you. If you held VCX before the listing through Fundrise's private offerings, this article is especially for you.

The most important date for Fundrise Innovation Fund (NYSE: VCX) investors in 2026 was August 13, 2026 — the day the lockup on restricted shares expired (accelerated by Fundrise on July 24 from the original ~September schedule). Since August 14, approximately 100,000 pre-IPO holders have been free to sell into the open market. This article was written before that date as a forecast; it is kept as written, with the outcome recorded at the top and dated updates where the tape contradicted it.

For the broader VCX review (NAV mechanics, holdings, fee structure, the case for and against owning VCX at any price), see Fundrise VCX Review 2026. This article focuses narrowly on the lockup event, the supply dynamics around it, the DXYZ precedent, and a practical framework for what to do.

Update — August 13, 2026: Unlock Day, and the Affiliates Already Sold

This is the last read before the shares trade. Two things have changed since the July read: the price has kept grinding lower into the date rather than settling, and the Form 144 record revealed who was selling while everyone else was locked up.

Price: VCX closed at $34.40 on August 14, 2026, the first session unlocked shares could trade, down 10.65% on record volume of 3,820,606 to 3,863,203 shares. August has run $36.40 (Aug 3), $34.99, $33.00, $32.91, $34.45, $32.86, $31.70, $31.89, $38.50, then $34.40. The lowest close since listing remains $31.70 on August 11; the lowest trade ever is $28.71, printed intraday on unlock day.

On the drawdown figure, a correction to what this page said yesterday. It previously described VCX as "off roughly 63% from the June peak." That is measured from the June 30 close of $86.43, which was itself already 77% below the fund's record. Measured from the record close of $380.00 (March 25, 2026), VCX is down 91.6%; from the $575.00 intraday high, 94.5%. We have published the complete session-by-session record — all 101 sessions from listing day — so the reference point is checkable rather than asserted. The market has priced most of the supply wall in advance rather than waiting for it, but "priced in and settled" is not what the tape says: the fund set new closing lows on August 10 and August 11, three and two sessions before the date.

Premium: against the NAV of $18.97 per share reported in the fund's SEC Form N-CSR for the period ended March 31, 2026, $31.70 is a premium of roughly 1.67x, or about 67% — down from ~193% ($55.62) at the July 24 close, ~205% ($57.86) on July 20, ~353% ($86) in late June and ~309% ($77.56) on July 2. The premium compressed through the ~2x-NAV level in the direction the DXYZ template predicted, and it did so before the August 13 date, not after.

(Note: a previous version of this article used a NAV of $18.43. That figure was wrong and we could not substantiate it against any primary source. All premium figures here are now calculated against the $18.97 per-share NAV stated in the fund's own SEC filing — $678,918 thousand in net assets across 35,797,138 shares.)

The disclosed affiliate selling

Here is the part almost no other coverage has picked up, and it comes from the fund's own filings.

Rule 144 requires affiliates of an issuer to file a Form 144 before selling, and to disclose what they sold over the prior three months. The notices state that the shares were acquired on February 24, 2026 in a "Registered Offering on Form N-2", after the February 20 lockup cutoff, so they were never locked up; the seller is described as a wholly-owned subsidiary of Fundrise Real Estate Interval Fund, LLC. VCX's filings show that while ~100,000 ordinary restricted holders were locked up and unable to sell, Fundrise-affiliated entities were selling on the open market nearly every trading day:

• 889,081 shares sold for $56,493,338 gross between June 2 and August 11, 2026, by Tech Infrastructure REIT, LLC — an entity listed at 11 Dupont Circle NW, Washington DC, the same address as the Fundrise Innovation Fund on the same filing.
• Average realized price: $63.54 per share — roughly 3.3x the fund's $18.97 NAV, and about 1.7x where VCX trades today.
• The pace accelerated as the price fell: 7,316 shares on July 23, then 47,197 on July 27 and 45,204 on July 28.
• On August 3, 2026, a further Form 144 was filed for the account of Fundrise Real Estate Interval Fund, LLC (SEC CIK 0001777677, same address) noticing the sale of 353,788 shares (~$11.68 million) through Jefferies LLC — ten days before retail unlocks.

The 889,081 shares sold are about 2.5% of the 35,797,138 shares outstanding reported in the fund's own Form N-CSR for the period ended March 31, 2026, and about 3.1% including the 202,915 shares noticed on August 12, all sold or noticed by sponsor-side entities ahead of the retail unlock. The August 3 notice overlaps the 889,081: 329,105 of its shares were sold August 3-11 and are already in that total (our arithmetic). (Quote sites carry a smaller share count of about 28.35 million, the pre-listing count; against that denominator the same figures are ~3.1% and ~3.9%. We use the filed number.)

This is legal, and it was disclosed. Form 144 exists precisely so this information reaches the market, and Fundrise filed it properly. It is not evidence of wrongdoing. But it is directly material to the question this article asks. The supply-wall thesis assumed the pressure arrives on August 14 when retail unlocks. The filings show a meaningful share of the selling pressure was already in the market through June and July, from sellers who did not have to wait — and who realized an average price more than double what the unlocking retail base can get today.

Primary sources: Form 144 filed August 3, 2026 and July 24, 2026, Fundrise Innovation Fund, LLC (SEC CIK 0001867090).

Why that matters for the thesis. The July 1 version of this section argued the market had not front-run the unlock — that the premium was still intact and so the unlock window itself was the moment of maximum risk. That has partly reversed. Over July the market has aggressively priced the supply wall in, and buyers who paid $86–99 in June are already sitting on a 60%+ drawdown. Two things follow. First, the DXYZ analog — an 80%+ compression once unlock dynamics take hold — is now playing out on VCX in real time, not just in theory. Second, the risk is no longer purely "wait for August": compression has already started, yet ~100,000 restricted holders with a $10–11 cost basis still cannot sell until ~August 13, so the largest block of latent supply remains ahead of us. The framework in the rest of this article — partial de-risking on multi-baggers, the DXYZ compression template, the absorption-rate scenarios — is now being validated by price, not merely modeled.

The mechanics changed in one important way since this section was first written: on July 24, 2026 Fundrise accelerated the lockup expiration by one month, to August 13, 2026 (tradeable Aug 14) — earlier than the original ~September schedule, which pulls the supply wall forward. The Citron overhang has also crystallized — Andrew Left was convicted of securities fraud on June 1, 2026 (a Los Angeles federal jury found him guilty on 13 of 17 counts; sentencing was scheduled for August 31, 2026). The dated figures elsewhere in this article are preserved as of their original April–July 2026 reporting for the historical record; the numbers above are the current read.

How the VCX Lockup Works

The Innovation Fund (VCX) listed on the NYSE on March 19, 2026 via direct listing (not a traditional IPO). Pre-listing investors bought shares in the fund's registered offering (the fund describes itself as "a publicly registered, non-diversified, closed-end management investment company") while it operated as a tender-offer fund with limited liquidity, accumulating positions over multiple years from the fund's July 2022 inception. At listing, shares bought before February 20, 2026 became subject to a six-month lockup that shareholders approved on February 19, 2026.

The six-month lockup period: restricted shares cannot be sold on the public market for six months after the listing date. This is a customary lockup structure for direct listings of previously-private vehicles, designed to prevent immediate flooding of the market and allow price discovery.

Expiration date: August 13, 2026, now past. The original schedule was ~September (six months after listing); on July 24, 2026 the Fund chose to accelerate the expiration by one month, from September 14 to August 13. Restricted shares first traded August 14.

The Math That Matters

This is the part that almost all coverage skips.

Total share count

VCX has 35,797,138 common shares outstanding as of March 31, 2026 — stated on the balance sheet of the fund's SEC Form N-CSR, the same document that gives the $18.97 NAV ($678,918 thousand of net assets / 35,797,138 shares). Third-party quote sites carry roughly 28.35 million shares and compute market cap from that, a ~21% smaller number than the filing. That is the pre-listing count: the fund's January 2026 tender offer reported approximately 28,311,299 shares outstanding at January 29, 2026, and the Form 144 notices still use 28.3-28.35 million. The fund's September 2026 N-2 reports the same 35,797,138 as of September 8, 2026, so every percentage on this page uses the filed figure.

Restricted vs. unrestricted split

The fund's filings do not break out restricted (locked) and unrestricted (freely tradeable) shares; the lockup applied to shares bought before February 20, 2026. Form 144 affiliate-resale notices were filed via Jefferies LLC between March 25 and April 24, 2026; the April 14 notice, for example, covered 60,753 shares (about $6.93 million), and the 28.3 million figure on that form is the issuer's shares outstanding, not the shares to be sold. Form 144 is a notice of intent to sell, not an actual sale.

What we know with confidence:

• ~100,000 retail investors held VCX through Fundrise's pre-listing offering at listing (multiple sources, including Citron's report and Fundrise's own disclosures).
• These investors' shares were subject to the six-month lockup until it expired on August 13, 2026.
• A material fraction of total shares outstanding is restricted.

Daily trading volume

Updated August 15, 2026, because the old figure on this page was never the right baseline. This page previously cited "approximately 150,000-160,000 shares per day," measured in the April 22-29 window. Against the full tape that badly understates the current market. Median daily volume is 271,454 shares across the 102 sessions before the unlock, 219,826 over the 20 sessions to August 12, and 120,297 during the quiet July 1-24 lull, which is where the widely repeated 150,000 figure most likely originated. Unlock day, August 14, traded 3,820,606 to 3,863,203 shares, the heaviest session in the fund's history: roughly 17x the 20-session median, or a misleading 26x if you use the bogus 150,000 baseline.

This matters for how Friday gets reported. Against a 150,000 baseline, a one-million-share day reads as "6.7x normal"; against the honest 20-session median it is 4.5x. When you see an unlock-day volume multiple quoted anywhere, including here, check which baseline and which window it uses. Full figures in the complete VCX price record.

The supply-shock arithmetic

The pre-unlock arithmetic ran like this (kept as written; the outcome is in the August 21 update above). If even 5% of restricted holders attempted to sell on or shortly after August 13, 2026, that would introduce approximately 5,000 sellers into a market accustomed to absorbing 150,000 shares of total volume per day. With position sizes likely in the 100-1,000 share range per investor (the filed share count implies about 358 on average: 35.8 million shares across ~100,000 investors; our arithmetic), 5% selling could mean 500,000 to 5 million shares of sell pressure trying to clear the order book in days, not months.

Put differently: if pre-IPO investors are sitting on gains of up to ~8x at the April price and a non-trivial fraction decide to crystallize, the supply imbalance could force the price down materially before sellers exit.

This is the structural concern. It is not Citron's invention — it is plain order-book mechanics.

The DXYZ Precedent

The closest analog to VCX is Destiny Tech100 (NYSE: DXYZ), a similar listed closed-end fund holding stakes in private technology companies including SpaceX, OpenAI (via SPV), Anthropic (via SPV), Stripe, Epic Games, and others. DXYZ listed on the NYSE on March 26, 2024 — exactly two years before Citron's VCX short report on March 26, 2026 (intentional or coincidence is anyone's guess).

DXYZ's price history is a precise template for what unlocked supply does to a premium-to-NAV trade.

The pattern: DXYZ went from a 1,900% premium to a ~65% premium over 24 months, but not in a straight line. The first leg took three weeks; after ~250% on April 30, 2024 the premium re-expanded to ~814% by year-end 2024 ($58.86 close vs $6.44 NAV), then compressed to ~54% by year-end 2025 ($30.63 close vs $19.93 NAV). By the September 11, 2026 close of $32.11, DXYZ traded at a 6.4% discount to its $34.30 NAV at June 30, 2026 (our arithmetic throughout).

The critical observation: DXYZ's NAV rose 209.6% in 2025 alone (from $6.44 to $19.93) and reached $34.30 by June 30, 2026 as underlying holdings marked up. The price still fell 82% from the peak within three weeks in April 2024, and on April 29, 2026 it was 67% below the $99.79 peak close (our arithmetic). The premium did the damage; the underlying performed.

Same dynamic applies to VCX. Even if Anthropic ($380B Series G February 2026, possibly $850-900B in current talks per Bloomberg) and OpenAI ($852B post-money in the round VCX announced it joined on April 1, 2026) continue to mark up, the premium-to-NAV is the dominant variable in VCX's price.

What's Different About VCX vs. DXYZ

Three meaningful differences argue VCX may compress faster, slower, or differently than DXYZ.

1. xStocks tokenization (a relief valve DXYZ never had)

On March 27, 2026 — one day after Citron's report — Fundrise announced VCXx, a tokenized version of VCX issued via Backed Assets (JE) Limited and Payward Digital Solutions Ltd. The tokens are backed 1:1 by underlying VCX shares and trade on Kraken's xStocks platform globally.

Critical caveat: VCXx is not available to U.S. persons. It addresses non-US demand for VCX exposure but does not directly route to the NYSE order book. The relief valve is real but partial — non-US holders who would otherwise have no exit may use VCXx, while US-based pre-IPO holders still need NYSE liquidity to crystallize gains.

DXYZ never had this. It is a meaningful structural difference.

2. How each fund holds OpenAI

DXYZ's OpenAI position is held via a stacked SPV — and OpenAI has publicly disavowed recognition of secondary SPVs holding its shares (per PitchBook reporting). VCX announced on April 1, 2026 that it participated in OpenAI's funding round at $852B post-money, but its filings show its OpenAI exposure is held through co-investment vehicles: $84.2 million, 12.4% of net assets, at March 31, 2026, per the N-CSR schedule of investments.

This affects NAV reliability, not lockup mechanics, and on the evidence of the filings neither fund holds OpenAI directly.

3. Investor base size

DXYZ has thousands of holders. VCX has approximately 100,000 holders from Fundrise's pre-IPO private offerings — by far the largest retail base of any listed private-markets vehicle. This cuts two ways:

• Bullish read: Wider, less-concentrated holder base means individual sell decisions are less coordinated. Some holders will hold for the long term.
• Bearish read: Larger restricted base means larger total potential supply at unlock. Even a small percentage selling represents significant absolute volume.

The honest answer: nobody knows the percentage of unlocked holders who will sell. Investor surveys would help; none has been published.

The Citron Report Context

On March 26, 2026, Citron Research — the firm founded by Andrew Left, who was convicted of securities fraud on June 1, 2026 (a Los Angeles federal jury found him guilty on 13 of 17 counts; sentencing was scheduled for August 31, 2026) — published a short thesis on VCX via X (Twitter). The thesis specifically cited the lockup expiration as a near-term catalyst:

"When that lockup expires, they will all be looking at the same exit at the same time."

VCX fell from its $380.00 record close on March 25 to $262.00 on March 26, the day of the report — a 31.1% one-day decline, after trading as low as $182.01 intraday. By April 29, the stock had stabilized around $85, representing approximately 85% compression from the March 25 all-time high of $575.

The messenger problem: Andrew Left is a deeply impaired source — now a convicted one. He was indicted by the DOJ on July 25, 2024 on 19 felony counts (one securities-fraud scheme, 17 securities fraud counts, one count of false statements to federal investigators), and on June 1, 2026 a Los Angeles federal jury convicted him on 13 of the 17 counts, with sentencing scheduled for August 31, 2026. The SEC's parallel civil charges alleging a ~$20M fraud scheme remain outstanding. The conviction strengthens, rather than resolves, the case for discounting Citron's messaging — but not the underlying lockup math, which stands independent of who first flagged it.

Despite the impaired messenger, the lockup math itself is not in dispute. Citron's structural observation about August 13, 2026 is the same observation any honest analyst would make from public filings.

Fundrise / Ben Miller's Counter-Narrative

Ben Miller (Fundrise CEO) addressed Citron's thesis in an interview on CNBC on March 27, 2026 — the day after the short report. As Sherwood News reported it, Miller said his firm can't control the stock price and noted that pre-IPO investors were actually worried the fund would end up trading at a discount, not a premium.

Fundrise emphasized it rejected hedge-fund allocations during the listing in favor of distributing shares directly to its 100,000+ retail investors.

The OpenAI participation announcement on April 1, 2026 (BusinessWire) was a deliberate counter-narrative, demonstrating that VCX's underlying holdings are growing in valuation through legitimate funding rounds — not via opaque secondary marks.

What Fundrise has NOT done as of April 30, 2026:

• Filed a Form 8-K or supplemental N-CSR/N-2 disclosure responding to Citron
• Filed a defamation or other lawsuit against Citron
• Disclosed plans to extend or waive the lockup
• Disclosed how the company would manage liquidity around the August 13, 2026 unlock

The silence on the last item is the most material signal. A direct-listing manager confident in lockup absorption would typically pre-message the market. Fundrise has not.

What This Means for Different VCX Holders

If you are a pre-IPO holder with restricted shares

Your shares unlocked on August 13, 2026 and have been sellable since August 14. The decision framework below was written before the unlock and is kept because the choices are the same after it:

If you bought VCX on the open market post-listing

You did not have restricted shares. Your shares are already unrestricted and tradeable.

If you bought near the peak ($575 on March 25), you're already down ~85%. The lockup expiration adds further downside risk to a position already underwater. Realistic decisions:

• Tax-loss harvesting may be worth considering if you held in a taxable account.
• Averaging down ahead of August 13 is structurally adverse — supply pressure is incremental, not absorbed.
• Holding through the lockup is a directional bet on absorption + underlying NAV growth outpacing premium compression.

If you bought after the Citron decline (April $130, $90, $80 range), your position is closer to NAV. Premium compression risk is lower in absolute dollars, but the lockup remains a structural overhang. Position-sizing matters more than entry price.

If you do not own VCX

You are reading this because you're considering buying. The honest answer: why are you trying to be the buyer of pre-IPO shares unlocking onto the public market in 5 months? (Written in April 2026; the unlock came on August 14.)

The structurally favorable entry point for VCX is after the lockup expiration, after the supply shock has cleared, and after the premium has found its new equilibrium. That equilibrium may be 50-100% above NAV (the DXYZ post-shock baseline) or higher if Fundrise's larger investor base and lower fees earn a structural premium. Buying now, before that price discovery, requires a high-conviction thesis on premium retention through the unlock.

A reasonable wait-and-see position was to monitor the trading days after August 13, 2026, watch for the price floor, and consider entering only after the supply had cleared. Those days have now traded: see the August 21 update at the top for what the floor actually was. This is what most institutional allocators waiting on private-markets liquidity events typically do.

Frequently Asked Questions

Sources

Primary sources:

• Fundrise Innovation Fund LLC EDGAR profile (CIK 1867090)
• Fundrise official VCX page
• Fundrise/Kraken xStocks announcement (March 27, 2026)
• BusinessWire — VCX participates in OpenAI $122B round (April 1, 2026)
• SEC vs. Andrew Left (2024 Press Release)
• Bloomberg — Left loses motion to dismiss (Dec 2025)
• Anthropic Series G $380B (CNBC, Feb 12, 2026)
• Anthropic $900B talks (Bloomberg, April 29, 2026)

Secondary sources:

• StockTwits — Citron shorts VCX, calls SEC investigation
• Benzinga — VCX crashes 50% on Citron call
• Bloomberg — VCX slides after short report
• Sherwood News — Fundrise VCX falls amid valuation gap
• TipRanks — Ben Miller addresses skeptics
• TipRanks — VCX vs DXYZ post-attack
• Yahoo Finance — VCX vs DXYZ proxies
• Morningstar — DXYZ "Not Destiny's Child"
• PitchBook — OpenAI SPV contested
• Financial Samurai — VCX listing analysis
• InvestorPlace — VCX frenzy warning
• StockAnalysis.com VCX page
• StockAnalysis.com DXYZ page

Internal links: Fundrise VCX Review 2026 (broader review) · Fundrise VCX vs DXYZ comparison · Fundrise Review 2026 · Fundrise Portfolio Comparison · Fundrise vs REITs · Real Estate Crowdfunding Risks